Berlanga P - Search Results

1

Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.

Sanmartín E, Muñoz L, Piqueras M, Sirerol JA, Berlanga P, Cañete A, Castel V, Font de Mora J. Sanmartín E, et al. Among authors: berlanga p. Clin Cancer Res. 2017 Nov 15;23(22):6875-6887. doi: 10.1158/1078-0432.CCR-17-0593. Epub 2017 Aug 22. Clin Cancer Res. 2017. PMID: 28830922

2

Emerging drugs for neuroblastoma.

Castel V, Segura V, Berlanga P. Castel V, et al. Among authors: berlanga p. Expert Opin Emerg Drugs. 2013 Jun;18(2):155-71. doi: 10.1517/14728214.2013.796927. Epub 2013 May 22. Expert Opin Emerg Drugs. 2013. PMID: 23692586 Review.

3

Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience.

Berlanga P, Cañete A, Díaz R, Salom M, Baixauli F, Gómez J, Llavador M, Castel V. Berlanga P, et al. J Pediatr Hematol Oncol. 2015 Jul;37(5):e272-7. doi: 10.1097/MPH.0000000000000270. J Pediatr Hematol Oncol. 2015. PMID: 25374283

4

Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution Experience.

Diaz-Beveridge R, Lorente D, Torres B, Cañete A, Rodrigo E, Bruixola G, Berlanga P, Reche E, Montalar J, Verdeguer A, Aparicio J. Diaz-Beveridge R, et al. Among authors: berlanga p. J Pediatr Hematol Oncol. 2015 Jul;37(5):e278-84. doi: 10.1097/MPH.0000000000000339. J Pediatr Hematol Oncol. 2015. PMID: 25929608

5

Cancer in children and adolescents in Spain: incidence, treatment setting and provider specialty.

Berlanga P, Vicente ML, Cañete A, Alberich C, Castel V. Berlanga P, et al. Clin Transl Oncol. 2016 Jan;18(1):27-32. doi: 10.1007/s12094-015-1330-y. Epub 2015 Jun 25. Clin Transl Oncol. 2016. PMID: 26108409

6

Paediatric tumour boards in Spain: a national survey.

Berlanga P, Segura V, Juan Ribelles A, Sánchez de Toledo P, Acha T, Castel V, Cañete A. Berlanga P, et al. Clin Transl Oncol. 2016 Sep;18(9):931-6. doi: 10.1007/s12094-015-1466-9. Epub 2015 Dec 22. Clin Transl Oncol. 2016. PMID: 26693730

7

Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.

Berlanga P, Cañete A, Salom M, Montalar J, Guasp M, Marco A, Castel V. Berlanga P, et al. J Pediatr Hematol Oncol. 2016 Apr;38(3):176-81. doi: 10.1097/MPH.0000000000000546. J Pediatr Hematol Oncol. 2016. PMID: 26925713

8

miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis.

Berlanga P, Muñoz L, Piqueras M, Sirerol JA, Sánchez-Izquierdo MD, Hervás D, Hernández M, Llavador M, Machado I, Llombart-Bosch A, Cañete A, Castel V, Font de Mora J. Berlanga P, et al. Mol Oncol. 2016 Aug;10(7):1043-53. doi: 10.1016/j.molonc.2016.04.004. Epub 2016 Apr 23. Mol Oncol. 2016. PMID: 27155790 Free PMC article.

9

[The new challenge in oncology: Next-generation sequencing and its application in precision medicine].

Calabria I, Pedrola L, Berlanga P, Aparisi MJ, Sánchez-Izquierdo D, Cañete A, Cervera J, Millán JM, Castel V. Calabria I, et al. Among authors: berlanga p. An Pediatr (Barc). 2016 Nov;85(5):273.e1-273.e7. doi: 10.1016/j.anpedi.2016.05.006. Epub 2016 Jun 24. An Pediatr (Barc). 2016. PMID: 27349697 Free article. Review. Spanish.

10

Advances in emerging drugs for the treatment of neuroblastoma.

Berlanga P, Cañete A, Castel V. Berlanga P, et al. Expert Opin Emerg Drugs. 2017 Mar;22(1):63-75. doi: 10.1080/14728214.2017.1294159. Epub 2017 Feb 22. Expert Opin Emerg Drugs. 2017. PMID: 28253830 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters